Published in Front Pharmacol on February 12, 2015
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. Front Immunol (2015) 1.08
Targeting natural killer cells in cancer immunotherapy. Nat Immunol (2016) 1.06
NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer (2015) 1.04
Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies. Front Immunol (2015) 0.88
Utilizing chimeric antigen receptors to direct natural killer cell activity. Front Immunol (2015) 0.85
Advances in clinical NK cell studies: Donor selection, manufacturing and quality control. Oncoimmunology (2015) 0.84
Development of Novel Immunotherapies for Multiple Myeloma. Int J Mol Sci (2016) 0.82
Improving natural killer cell cancer immunotherapy. Curr Opin Organ Transplant (2015) 0.80
Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy. Front Immunol (2016) 0.78
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget (2016) 0.77
Preclinical targeting of aggressive T cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia (2017) 0.77
Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation. Front Immunol (2017) 0.76
Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther (2017) 0.76
Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment. Front Immunol (2017) 0.75
Manufacturing Natural Killer Cells as Medicinal Products. Front Immunol (2016) 0.75
Modeling Natural Killer Cell Targeted Immunotherapies. Front Immunol (2017) 0.75
Editorial: Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol (2015) 0.75
Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy. Exp Mol Med (2017) 0.75
Automated enrichment, transduction and expansion of clinical-scale CD62L+ T cells for manufacturing of GTMPs. Hum Gene Ther (2016) 0.75
Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma. Front Immunol (2017) 0.75
In Vitro Generation of Human NK Cells Expressing Chimeric Antigen Receptor Through Differentiation of Gene-Modified Hematopoietic Stem Cells. Methods Mol Biol (2016) 0.75
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol (2017) 0.75
Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children. Oncotarget (2017) 0.75
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. Front Immunol (2017) 0.75
Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Target Oncol (2017) 0.75
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. Front Immunol (2017) 0.75
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Graft-versus-host disease. Lancet (2009) 8.78
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 7.28
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest (2008) 7.05
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature (2010) 6.95
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science (2013) 5.64
Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science (2013) 5.34
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med (2010) 4.76
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science (1997) 4.58
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther (2010) 4.54
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood (2013) 3.45
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood (2005) 2.81
Functional characterization of a signal transducing motif present in the T cell antigen receptor zeta chain. J Exp Med (1993) 2.17
Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med (2014) 2.00
Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy (2010) 1.85
Treating cancer with genetically engineered T cells. Trends Biotechnol (2011) 1.83
Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood (2014) 1.78
Improved artificial death switches based on caspases and FADD. Hum Gene Ther (1999) 1.68
A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy (2012) 1.67
Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood (2009) 1.57
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia (2004) 1.56
Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest (2012) 1.53
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia (2013) 1.52
Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood (2002) 1.48
A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med (2014) 1.42
The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther (2007) 1.40
Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One (2011) 1.39
A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia (2000) 1.36
Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther (2009) 1.32
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother (2007) 1.27
Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr (2005) 1.26
Use of NK cell activity in cure by transplant. Br J Haematol (2011) 1.22
Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology (2013) 1.21
IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA. Eur J Immunol (2010) 1.20
Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant (2012) 1.18
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A (2008) 1.18
Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy (2013) 1.17
NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med (2012) 1.16
2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res (2009) 1.15
Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother (2012) 1.13
IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. J Immunother (2010) 1.11
Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies. Front Immunol (2014) 1.10
Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res (2009) 1.10
IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis (2004) 1.09
Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther (2014) 1.08
Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy (2003) 1.08
A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res (2013) 1.02
Signatures of human NK cell development and terminal differentiation. Front Immunol (2013) 1.02
Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther (2013) 1.01
T-cell immunotherapy: looking forward. Mol Ther (2014) 1.00
An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol Ther (2010) 1.00
Are natural killer cells superior CAR drivers? Oncoimmunology (2014) 0.99
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother (2012) 0.98
Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol (2013) 0.97
Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther (2011) 0.97
IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. PLoS One (2011) 0.97
Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol (2013) 0.96
Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol (2014) 0.94
Genetic modification of lymphocytes by retrovirus-based vectors. Curr Opin Immunol (2012) 0.91
Evidence for the role of class I and class II HLA antigens in the lytic function of a cloned line of human natural killer cells. J Immunol (1985) 0.89
Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody. Immunol Cell Biol (2013) 0.87
Natural killer cell alloreactivity 10 years later. Curr Opin Hematol (2012) 0.86
Natural killer cell lines in tumor immunotherapy. Front Med (2012) 0.86
Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. Anticancer Res (2007) 0.86
Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells (2014) 0.85
Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy. Cancer Immunol Immunother (2014) 0.83
Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors. Curr Gene Ther (2014) 0.83
Regulatory requirements for clinical trial and marketing authorisation application for gene therapy medicinal products. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2010) 0.81
Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res (2014) 0.80
Natural killer cell reprogramming with chimeric immune receptors. Methods Mol Biol (2013) 0.78
Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody. MAbs (2015) 0.76